My Learning Cart
?
Categories
Account

Which company received FDA approval in 2022 for a gene therapy targeting a rare

₹0.0
Login to Download
  • 📥 Instant PDF Download
  • ♾ Lifetime Access
  • 🛡 Secure & Original Content

What’s inside this PDF?

Question: Which company received FDA approval in 2022 for a gene therapy targeting a rare genetic disorder?

Options:

  1. Novartis
  2. Bluebird Bio
  3. Spark Therapeutics
  4. CRISPR Therapeutics

Correct Answer: Bluebird Bio

Solution: 

In 2022, Bluebird Bio received FDA approval for its gene therapy targeting beta-thalassemia, a rare genetic blood disorder.

Which company received FDA approval in 2022 for a gene therapy targeting a rare

Practice Questions

Q1
Which company received FDA approval in 2022 for a gene therapy targeting a rare genetic disorder?
  1. Novartis
  2. Bluebird Bio
  3. Spark Therapeutics
  4. CRISPR Therapeutics

Questions & Step-by-Step Solutions

Which company received FDA approval in 2022 for a gene therapy targeting a rare genetic disorder?
  • Step 1: Identify the year in question, which is 2022.
  • Step 2: Look for companies that received FDA approval in that year.
  • Step 3: Focus on gene therapies that were approved.
  • Step 4: Find out which gene therapy targets a rare genetic disorder.
  • Step 5: Confirm that Bluebird Bio received FDA approval for its gene therapy.
  • Step 6: Specify that the gene therapy targets beta-thalassemia, a rare genetic blood disorder.
No concepts available.
Soulshift Feedback ×

On a scale of 0–10, how likely are you to recommend The Soulshift Academy?

Not likely Very likely
Home Practice Performance eBooks